T세포요법 세계 시장 규모는 2022년 28억 3,000만 달러로 평가되었고, 2023년 38억 3,000만 달러에서 2031년에는 430억 달러로 성장해 예측기간 중(2024-2031년) CAGR은 35.3%로 성장할 전망입니다.
암은 여전히 세계의 주요 사망 원인 중 하나이며 2040년까지 2,750만 명의 환자가 늘어날 것으로 예측되고 있습니다. 그러나 오랫동안 관해를 지속시키는 것은 여전히 어려움입니다. 포를 효과적으로 표적으로 하고 배제하는 능력이 있기 때문에 지지를 모으고 있습니다. 이러한 솔루션으로 자리매김하고 있습니다. 이러한 세포요법의 개발이 가속화되고 있는 가운데, 이 신흥 부문은 바이오 의약품 업계에서 가장 유리한 시장의 하나가 될 준비가 되어 있습니다.
Global T-Cell Therapy Market size was valued at USD 2.83 billion in 2022 and is poised to grow from USD 3.83 billion in 2023 to USD 43.0 billion by 2031, growing at a CAGR of 35.3% during the forecast period (2024-2031).
Cancer remains one of the leading causes of mortality worldwide, with projections indicating an addition of 27.5 million cases by 2040, imposing heavy financial, emotional, and physical strains on individuals and healthcare systems alike. While existing treatment options can slow disease progression, achieving long-lasting remission remains a challenge. In response, immunotherapies, particularly T-cell therapies such as CAR-T, TCR, and TIL therapies, are gaining traction for their ability to effectively target and eliminate tumor cells with fewer side effects. This innovative approach harnesses the human immune system's power, positioning T-cell therapy as a transformative solution in cancer treatment. As the development of these cell therapies continues to accelerate, this emerging sector is poised to become one of the most lucrative markets in the biopharmaceutical industry.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global T-Cell Therapy Market Segmental Analysis
Global T-Cell Therapy Market is segmented by therapy type, modality, indication, end-user and region. Based on therapy type, the market is segmented into CAR T-cell therapy, tumor-infiltrating lymphocytes (TIL) therapy and t cell receptor (TCR)-based therapy. Based on modality, the market is segmented into research use and clinical use. Based on indication, the market is segmented into hematologic malignancies, solid tumors, infectious diseases and autoimmune diseases. Based on end-user, the market is segmented into hospitals, cancer treatment centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global T-Cell Therapy Market
The Global T-Cell Therapy market is being significantly driven by the recent FDA approvals of Yescarta, Kymriah, and Tecartus, prompting numerous companies to pivot from developing traditional protein and small-molecule therapeutics to focus on adoptive therapies as their core business strategy. This shift has led to a remarkable increase in the T-cell therapy market, bolstered by strategic investments from both public and private sectors. The burgeoning gene therapy landscape plays a crucial role, as these advancements enhance the efficacy of CAR-T therapies. Additionally, the integration of T-cell approaches in cancer immunotherapy, combined with substantial funding dedicated to CAR T-cell research, is expected to propel the market, particularly with an expanding clinical trial environment for various hematologic cancers.
Restraints in the Global T-Cell Therapy Market
The T-cell therapy market faces significant constraints primarily due to the limited effectiveness of CAR-T therapies in treating solid tumors, compounded by safety concerns arising from the highly immunosuppressive tumor microenvironment. These challenges hinder market expansion, prompting industry stakeholders to explore innovative strategies to overcome these obstacles. Efforts are being made to enhance the applicability of CAR-T treatments in solid tumors, which may subsequently widen their therapeutic impact and improve patient outcomes. As the sector evolves, addressing these limitations will be crucial for tapping into the full potential of T-cell therapies in various oncological applications.
Market Trends of the Global T-Cell Therapy Market
The Global T-Cell Therapy market is witnessing a notable trend towards the application of CAR T-cell therapies in the treatment of solid tumors, particularly in challenging cases such as diffuse midline glioma, a rare and aggressive pediatric cancer. Research highlights the potential of CAR T-cell treatment to significantly improve patient outcomes, with successful trials showing extended tumor eradication in animal models despite facing toxicity challenges. Intracerebroventricular (ICV) delivery methods are emerging as a safer, more efficient alternative to systemic administration, marking a pivotal shift in therapeutic strategies. This evolving landscape is expected to drive substantial growth in the T-Cell Therapy market, attracting investments and innovations tailored for solid tumor applications.